Description: Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Home Page: www.advicenne.com
3ème étage 262
Paris,
75008
France
Phone:
33 1 85 73 36 20
Officers
| Name | Title |
|---|---|
| Mr. Didier Laurens | CEO, MD, General Director & Director |
| Mr. Laurent Cassedanne | Deputy CEO, Deputy GM & Head Pharmacist and Director |
| Isabelle Kervella | Chief Financial Officer |
| Dr. André Ulmann M.D., Ph.D. | Chief Medical Officer & Non-Voting Director |
| Ms. Hege Hellstrom | Chief Commercial Officer |
| Mr. Robbie McCarthy | General Manager of Advicenne Inc. |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 7.9416 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |